Larkspur Health (NASDAQ:LSPR) has entered into a definitive agreement to combine with specialty biopharmaceutical company ZyVersa at an enterprise value of $108.92 million. Weston, Florida-based ZyVersa is developing clinical and preclinical treatments for a variety of inflammatory diseases affecting the kidneys and nervous system. The combined company is expected to trade on the Nasdaq under the
Read More